@FierceMedDev: ICYMI: FDA approves ear inserts to reduce TMJ pain. Article | Follow @FierceMedDev
@StacyALawrence: ICYMI: Intel, Michael J. Fox Foundation start smartwatch study to track Parkinson's patients. Story | Follow @StacyALawrence
@VarunSaxena2: RT @FierceMedDev: We're looking for fierce women at the top of their game in med tech. Learn more about how to nominate. | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: Top U.S. senator urges Hospira to abandon inversion plans. Article | Follow @EmilyWFierce
> New Ebola detection devices are being developed to update the arduous blood testing procedures currently necessary to properly diagnose the disease. Story
> Varian Medical ($VAR) announced an additional 6 million shares for its repurchasing plans through December 31, 2015. Release
> Nirmidas Biotech, developer of a technology platform used to detect disease biomarkers, closed a seed funding round with $2 million. Release
> Cardiovascular diagnostics company diaDexus received a $15 million loan from Oxford Finance--some of the loan will go towards paying off existing debt. Release
Biotech News
@FierceBiotech: After a few days in Copenhagen, looks like Novo's fine today amounts to dinner for 6, with wine. Report | Follow @FierceBiotech
@JohnCFierce: Norway, Denmark and now Sweden. Too bad I won't make Finland. Should be interesting to see how Stockholm has changed in the last 10 years. | Follow @JohnCFierce
@DamianFierce: $NVO's CEO on the house that Victoza built and the future of diabetes R&D. Story | Follow @DamianFierce
@EmilyMFierce: ICYMI: Chikungunya vaccine shows antibody response in Phase I trial. Story | Follow @EmilyMFierce
> Novartis circles back with new terms for a stem cell biotech buyout--report. More
> Struggling Eisai files its thyroid cancer drug lenvatinib in U.S., EU. News
> Novo Nordisk accepts a $90K slap on the hand for delaying news of Tresiba setback. Report
> Are they or aren't they? Chugai spurns reports of Roche takeover talks. Article
Pharma News
@FiercePharma: Top-read on FP this weekend: Bloomberg: Roche negotiating for rest of Chugai for $10B. Report | Follow @FiercePharma
@TracyStaton: Been on vacay? FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. Story | Follow @TracyStaton
@EricPFierce: ICYMI last week: Zytiga fight heats up between J&J, NICE, stirred by anxious cancer patients. Story | Follow @EricPFierce
@CarlyHFierce: ICYMI Friday: FDA sets decision date for Pfizer's MenB candidate. More | Follow @CarlyHFierce
> Docs to FDA: Biosimilars should have different names than branded drugs. More
> Should deal-needy Pfizer target antibiotics specialist Cubist? Story
> Alabama Supreme Court redux: Pfizer can be sued for generic Reglan harms. Article
CRO News
> Shire bails out a contractor to keep its drug on the market. Report
> Evotec rides its risk-sharing model to revenue growth. Article
> AMRI swings to revenue growth amid a transitional year. News
> ABL teams up with Expression Therapeutics on a hemophilia treatment. Item
> Almac pours $90M into N. Ireland, adding 350 jobs. Story
Biotech IT News
> Validic raises $5M to fuel 'crazy' growth of data aggregation platform. News
> Top U.S. universities join project to apply Big Data to social problems. Item
> Oxford Nanopore raises $59M to scale up production of MinION sequencer. More
> Survey: Scientists talk on Twitter, network on ResearchGate. Story
> Pfizer continues to explore virtual trials with 23andMe pact. Article
Animal Health News
> Kindred Biosciences' loss grows in the face of development costs. Story
> Former Warner Chilcott CFO Paul Herendeen takes that spot at Zoetis. Item
> Sales of pet products take a dive at Central Garden & Pet. More
> Australia's Jurox launches anesthetic in U.S. two months after setting up American operations. Article
> Elanco closing former ChemGen plant, moving production to the U.K. More